AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04132479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500mg
Description: 1000mg taken orally every 12 hours for 14 days
Study NCT04132479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinidazole 500mg
Description: 500mg taken orally every 12 hours for 14 days
Study NCT04132479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole 20mg
Description: 20mg taken orally every 12 hours for 14 days
Study NCT04044430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT04044430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO
Study NCT04044430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04044430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02545946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vessel loop
Description: using the vessel loop to hold the place of the surgical wound that is made during I\&D
Study NCT02545946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional I&D with or without packing
Description: abscess will be drained with a traditional I\&D with or without packing (as deemed appropriate by ER doctor)
Study NCT02632877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone with MODD
Description: Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.
Study NCT02632877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketanserin
Description: Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.
Study NCT02478307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Study NCT02478307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Study NCT02478307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Cognitive Therapy
Study NCT00531206 — intervention group
Intervention type: DRUG
Intervention: Tipranavir
Study NCT00531206 — intervention group
Intervention type: DRUG
Intervention: Ritonavir
Description: low dose
Study NCT01906541 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ex-vivo gene-therapy
Description: transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector
Study NCT01785836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Formulation A
Description: Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
Study NCT01785836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Formulation B
Description: Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
Study NCT01785836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Formulation C
Description: Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
Study NCT01785836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone 5% Gel
Description: Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
Study NCT01631864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 was provided as 400 mg tablets.
Study NCT01631864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine was provided as 5 mg tablets.
Study NCT01631864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to LCZ696 and amlodipine.
Study NCT01631864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo to LCZ696 and amlodipine.
Study NCT00046865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupressure therapy
Study NCT00046865 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: acupressure therapy
Study NCT00046865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Study NCT00046865 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: management of therapy complications
Study NCT00046865 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: management of therapy complications
Study NCT00046865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nausea and vomiting therapy
Study NCT00046865 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nausea and vomiting therapy
Study NCT00046865 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: nausea and vomiting therapy
Study NCT00483496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)
Study NCT00483496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ti02 pigmentary 3% alone (formula RV3131A-MV1211)
Study NCT02498431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease
Study NCT02498431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention
Description: a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease
Study NCT02498431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary angiography
Description: is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels
Study NCT02498431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronary angiography
Description: is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels
Study NCT02498431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent, Medronic Resolute Integrity
Description: A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.
Study NCT02498431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent, Medronic Resolute Integrity
Description: A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.
Study NCT03639831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proprietary, standardized botanical extract
Description: 2 capsules/ day providing the proprietary botanical extract as unique active ingredient
Study NCT03639831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextrin)
Description: 2 capsules/ day providing no active component
Study NCT04201054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 50 mg of fluconazole administered orally in a single dose.
Study NCT03695237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate (LA)
Description: Administered intramuscularly as an injection
Study NCT01149109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide and lomustine
Study NCT01149109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Study NCT04725474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: visugromab (CTL-002)
Description: monoclonal antibody
Study NCT04324203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three-dimensional Virtual Reality and Horticultural Therapy
Description: VR is a realistic, three-dimensional, and virtual environment formed by a combination of computer software and hardware
Study NCT02956785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Dinoprostone; CTS, UK
Study NCT02956785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 mg Dinoprostone vaginal tablet; Pfizer, UK
Study NCT02956785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aquacryl hydrogel rod; HPSRx Enterprises, USA
Study NCT04095481 — intervention group
Intervention type: DEVICE
Intervention: Obalon Navigation/Touch System
Description: The NTS Compatible Obalon Balloon System does NOT require the use of radiographic verification prior to the inflation of the intragastric balloon
Study NCT00605215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered per dose and schedule specified in the arm description.
Study NCT00605215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Study NCT00605215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex®
Description: Avonex® will be administered per dose and schedule specified in the arm description.
Study NCT01300728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam 10% IVIG
Description: Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.~Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.
Study NCT01300728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.
Study NCT04528160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education and exercise
Description: PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will included genera exercise delivered at moderate intensity.
Study NCT01096654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ct-scan or adrenal vein sampling
Description: Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
Study NCT00589589 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endo Tool
Description: Computer tool to help achieve glucose control
Study NCT04528160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care delivered at primary care for older adults with pain.
Study NCT01606072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: 20 patients in 5 groups 4 each, advancing progressively to each dose level.
Study NCT01001975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreen Test Code: V53-028
Description: Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole
Study NCT01001975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreen Test Code: V53-030
Description: Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone
Study NCT01001975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard SPF 4 Sunscreen
Description: 8% Homosalate Standard SPF 4 Sunscreen
Study NCT01662167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single
Description: In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
Study NCT01662167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multipe
Description: In the multiple dose regimen, 1 mg/kg/day intramuscular methotrexate was given on days one, three, five and seven and 0.1 mg/kg/day intramuscular Citrovoram factor was administered on days two, four, six and eight until serum hCG level decreased 15% in 48 hours or four doses of methotrexate was given weekly until serum hCG level of 15 mlU/ml or less was obtained
Study NCT03769662 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: IL-10 transgene DNA plasmid injected into the knee synovial capsule
Study NCT04539080 — intervention group
Intervention type: PROCEDURE
Intervention: transversus abdominis plane block
Description: transversus abdominis plane block group
Study NCT00483496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bisoctrizole 10% alone (formula RV3131A-MV1237)
Study NCT00483496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)
Study NCT00483496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)
Study NCT00483496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)
Study NCT02413307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassion Focused Therapy (self-practice)
Description: Daily practice of the CFT exercises for a minimum of five minutes per day. This is completed for a period of three weeks.
Study NCT04084171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 with Control-IQ Technology + Dexcom G6
Description: Subjects will use the Tandem t:slim X2 with Control- IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].
Study NCT03710746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
Study NCT00483496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]
Study NCT00483496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0096 CR vehicle (formula RV3131A-MV1197)
Study NCT03710746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response and Attention Training
Description: Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
Study NCT00052585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT03769480 — intervention group
Intervention type: OTHER
Intervention: Muscle strength evaluation and Respiratory function Tests
Description: Muscle strength evaluation and Respiratory function Tests
Study NCT00052585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT00052585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00052585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT02995980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-Energy Contrast-Enhanced (DECE) mammography
Description: Contrast mammography
Study NCT02995980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital mammography
Description: routine digital mammography
Study NCT03326804 — intervention group
Intervention type: DEVICE
Intervention: H1 Hip Resurfacing Arthroplasty
Description: A non-porous non-cemented ceramic-on-ceramic hip resurfacing arthroplasty device
Study NCT00999544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 0mg
Description: Aprepitant 0mg, p.o. pretreatment
Study NCT03481309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal tDCS
Description: The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.
Study NCT03481309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cathodal tDCS
Description: The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.
Study NCT03481309 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.
Study NCT01775020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Study NCT03868137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 3 doses of Ibuprofen 800 mg
Study NCT03868137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study NCT01254409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRM-151
Description: Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.
Study NCT01254409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.
Study NCT02072759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnitine supplement
Description: Carnitine supplement (oral ingestion with meals)~Total dosage of 2g carnitine per day for 36 days.~* 1 carnitine supplement at breakfast (500mg)~* 1 carnitine supplement at lunch (500mg)~* 2 carnitine supplements at diner (2x 500mg=1000mg)
Study NCT02072759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01627366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan
Description: Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
Study NCT04491149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: In the intervention arm, women undergoing amniocentesis/foeticide will use virtual reality glasses during the procedure.
Study NCT03492359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thora-3Di
Description: Device that uses a grid of structured light to measure chest and abdominal wall movement
Study NCT03492359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body Plethysmography
Description: A pulmonary function test (PFT) for measuring total lung volume.
Study NCT03492359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: A pulmonary function tests (PFT) for measuring maximal forced expiratory flow and volume.
Study NCT03065309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: bolus dose
Study NCT02044783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling
Study NCT02369809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neovasculgen®
Description: Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).
Study NCT02369809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neovasculgen®
Description: Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).
Study NCT00262600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: once a day
Study NCT00262600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran dose 1
Description: twice daily
Study NCT00262600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran dose 2
Description: twice a day